|
Mission Statement: To offer support and education to patients and families suffering from Liver Diseases: Hep.A,B,C,Wilson’s Disease, Auto Immune Disease, Cirrhosis and others, and the treatments available. To offer support and education to patients and families dealing with liver transplantation. To help educate the public regarding Liver Disease and the need for Organ Donors. |
|
Birthdays: Ronnie M April 1 Karen B April 3 Bailey F April 5 Joseph C April 14 Frankee D April 15 Dorothy S April 30
|
|
CCLA April 2009 |
|
Our next Meeting: Tuesday April 14th 2009 7:00 pm-9:00pm Carolina Medical Center, Charlotte Blythe Blvd. 3rd Floor Tower Dining Room Featured speaker Dr. Michael Stadtmauer N.D., L.Ac. Naturopathic Doctor and Licensed Acupuncturist. area of expertise is all aspects of alternative medicine, chronic disease, GI disorders, hormone imbalance and pain.
Patients and family and friends are all welcome to attend! Free parking, refreshments
|
|
IMPORTANT NOTE TO HEP C PATIENTS!! Locteron, is in Phase 2 clinical trials and is the only controlled-release interferon alfa known to us to be currently in active clinical development for the treatment of chronic hepatitis C. Locteron is designed to improve upon the current standard of patient care, interferon alfa administered weekly in combination with the antiviral drug ribavirin, which is associated with significant side effects. In a 32-patient Phase 2a clinical trial of Locteron administered once every two weeks in combination with ribavirin, an early virologic response (EVR) was achieved by 100% (16/16) of hepatitis C patients treated with the two highest doses , the 480 and 640 microgram, or µg, doses. Achievement of EVR, which is a specified reduction in viral load, has been broadly established to be a prerequisite for long-term response in hepatitis C patients. In addition, reported side effects were fewer and less severe than previously reported with other interferon products currently marketed or in development.
|
|
|